Hypercon
Halozyme to Acquire Elektrofi for $750 Million, Expanding Drug Delivery Capabilities
Halozyme Therapeutics; Elektrofi; acquisition; drug delivery; Hypercon; biologics; subcutaneous delivery; milestone payments; microparticle technology; Q4 2025